Articles tagged with: ASH 2010 Daily Update
News»

Tuesday was the last day of the American Society of Hematology annual meeting in Orlando. The myeloma portion of the conference concluded with one session of talks in the morning about treatments under development.
The first talk was given by Dr. David Siegel of Hackensack University Medical Center in New Jersey. Dr. Siegel presented results from a study of single-agent carfilzomib in myeloma patients who had relapsed multiple times and did not respond to their last treatment (abstract).
Among the 257 evaluable participants, 24 percent achieved at least a partial …
News»

This Monday was the third full day of the American Society of Hematology 2010 annual meeting, and it was packed with multiple myeloma-related presentations. The Beacon published an update earlier today covering presentations made Monday morning. This article covers material from Monday afternoon and evening.
The first presentation of the afternoon was by Dr. Ruben Niesvizky of the Weill Cornell Medical College in New York. He reported on the results of a Phase 3 trial using Velcade (bortezomib)-based initial treatment (induction) regimens combined with weekly Velcade maintenance therapy (abstract).
Patients in this trial were newly …
News»

Monday was the third full day of “ASH 2010,” this year’s annual meeting of the American Society of Hematology. This day was the busiest of the entire meeting in terms of multiple myeloma-related material. Presentations summarizing the latest myeloma research stretched from 7 a.m. until 8 p.m.
The morning presentations from Monday will be covered in this update, and presentations from the afternoon and evening will be covered in another update later today.
The day featured a large number of presentations and posters about Velcade (bortezomib), examining its use in …
News»

Yesterday was the second full day of the 2010 American Society of Hematology annual meeting in Orlando. It was a particularly busy day in terms of material related to multiple myeloma, with numerous oral presentations during the day and an extensive poster session in the early evening.
One of the first presentations of the day was actually a press conference held to review the results of a Phase 3 study comparing the efficacy and safety of two different stem cell transplant regimens for multiple myeloma (abstract).
In one arm of this …
News»

The American Society of Hematology meeting swung into full gear yesterday. The day was full of invited talks and a poster session.
The morning kicked off with an education session in which attendees could learn about several myeloma-related topics.
The first presentation was by Dr. Ola Landgren from the National Cancer Institute and National Institutes of Health in Bethesda, Maryland. Dr. Landgren spoke about monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma, precursor diseases of multiple myeloma.
A study published by Dr. Landgren last year showed that all multiple myeloma patients have …